Screener
Geron GERN Liability related to sale of future royalties
Liability related to sale of future royalties at other companies
Other financials
Where this comes from
Reported directly by Geron in its filing.
Tagged under the XBRL concept gern:LiabilityRelatedToSaleOfFutureRoyaltiesCurrent.
The source filing: Geron’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:41 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000886744-26-000037
| Line item | JUNE 30,2026 | DECEMBER 31,2025 |
|---|---|---|
| Accounts payable | $8,805 | $11,257 |
| Accrued compensation and benefits | 9,106 | 30,497 |
| Operating lease liabilities | 1,013 | 1,000 |
| Liability related to sale of future royalties | 20,692 | 17,448 |
| Accrued liabilities | 30,715 | 51,340 |
| Total current liabilities | 70,331 | 111,542 |
| Noncurrent operating lease liabilities | 1,000 | 1,445 |
| Noncurrent liability related to sale of future royalties | 108,933 | 112,134 |
ITEM 1. FINANCIAL STATEMENTS (UNAUDITED)
FAQ
- What is Geron's liability related to sale of future royalties?
- Geron (GERN) reported liability related to sale of future royalties of $20.69M in Q2 2026.
- How has Geron's liability related to sale of future royalties changed year-over-year?
- Geron's liability related to sale of future royalties increased by 18.6% year-over-year, from $17.44M to $20.69M.
- What does liability related to sale of future royalties mean?
- This represents the portion of obligations arising from the monetization of future royalty streams that is due within the next twelve months. It reflects a financing arrangement where the company receives upfront capital in exchange for a portion of future drug revenue. This liability highlights the company's reliance on alternative financing to fund ongoing research and development activities.
Ask your AI about Geron's liability related to sale of future royalties.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude